throbber
LElTE%TO NATUW
`-..~«
`
`
`'.!(.'.>.1:\X‘ -:.-.*;:::5'i‘J.‘:’>35§’V.‘.',.‘ -1- --t =
`
`NATURE VOL. 302 24 MARCH 1983
`
`
`
`3“
`
`Table 3 Expression of Lyt
`
`.1 and Lyt 2.1 antigens by FACS analysis
`
`Control mice
`
`% Lymph node cells expressing
`Lyt 1.1
`Lyt 2.1
`83.6:1.l
`24.4-i 1.4
`
`24.2t0.7
`90.1 $0.6
`VAA-fed mice
`Non significant
`P < 0.001
`Student’s t-test
`difference
`
`lrnrnunofluorescently stained CBA lymph node cells wereszargalysed
`using FACS-II (Becton-Dickinson) as described previously '
`, but
`with the argon ion laser set at 300 mW, 488 nm and the photomultiplier
`tube (EMI 9524A) at 750 V with a fluorescence gain of 8 and a light
`scatter gain of 4. Data for each individual mouse were derived from
`the analysis of 5 x 10‘ lymph node cells. The fluorescein isothiocyanate-
`coupled rabbit anti-mouse immunoglobulin (obtained from Nordic) was
`selected for its binding to viable cells expressing immunoglobulin at
`the cell surface while producing negligible staining of other cells”. The
`values in the table were calculated after subtracting the count for
`immunoglobulin-positive cells and represent the mean ts.e. calculated
`from-seven determinations. These results have been repeated in two
`subsequent experiments.
`
`Our data are consistent with recent studies of Loveland and
`
`McKenzie2°'2‘ who have clearly shown that Lyt 1* T cells alone
`(depleted of Lyt 2* T cells) were sufiicient to restore immune
`responses generated against H-2 and non-H-2 alloantigens in
`ATXBM (adult thymectomized, irradiated and bone-marrow
`reconstituted) mice. Our data also corroborate their view“ that
`Lyt 1* cells have a central role in allograft responses. In either
`case, vitamin A acetate seems to be unique in that it enhances
`immune responses against an allograft when given by mouth
`and the mechanism of this action will require much further
`attention.
`
`In summary, these findings support the hypothesis" that the
`anti—cancer action of vitamin A acetate "'22 is mediated through
`an immunological process and we have shown that it acts by
`increasing the representation of the Lyt 1"2‘ phenotype in the
`T-cell population.
`We thank Dr G. L. Asherson for the gift of the F(ab’)2 rabbit
`anti-mouse immunoglobulin and Prof. I. F. C. McKenzie for
`the monoclonal antibodies. We thank Drs E. Simpson
`and B. E. Loveland for discussions and Mrs Pat McFarlane
`for preparation of the manuscript. This work was supported by
`the _CRC and MRC.
`'
`Received 1 December 1982; accepted 21 January 1983.
`
`_
`
`._...-.—.—“""!".°.“-79°>'9‘!-"
`
`1. Moore, T. in The Vitamin: (eds Sebrell, W. H. & Harris, R. S.) 245-266 (Academic, New
`York, 1967).
`2. Goodman, D. S. Fedn Prac. 38, 2501-2503 (1979).
`3. Bollag, W. in Rerinaids, Advances in Basic Research and Therapy (eds Orfanos, C; E. at
`al.) 5-11 (Springer. Berlin, 1981).
`.
`.5
`Spcrn. M. B. in Retinoids, Advances in Basic Research and Therapy (eds Orfanos, C. E.
`et al.) 73-76 (Springer. Berlin, 1981).
`Pawson, B. A. Ann. N. Y. Acad. Sci. 359, 1-8 (1981).
`Dresser, D. W. Nature 217, 527-529 (1968_).
`Floersheim, G. L. & Bollag, W. Transplantation 15, 564-567 (1972).
`Jurin. M. & Tannock, I. F. Immunology 23, 283-287 (1972).
`Cohen, B. E. & Cohen, 1. K. J. Immun. 111, 1376-1380 (1973).
`Blalock, J. E. & Gifiord, G. E. Prac. narn. Acad. Sci. U.S.A. 74, 5382-5386 (1977).
`Dennert, G. & Lotan, R. Eur. J. Immun. 8, 23-29 (1978).
`. Dennert, G., Crowley, C., Kouba, J. & Lotan, R. J. nam. Cancer Inst. 62, 89-94 (1979).
`. Goldfarb, R. H. & Herberman, R. B. J. Immun. 126, 2129-2135 (1981).
`14. Abb, 1., Abb, H. & Deinhardt, F. Imrnunapharmacalagy 4. 303-310 (1982).
`I5. Sporn, M. B. & Newton, D. L. Fedn Pine. 38, 2528-2534 (1979).
`16. Bollag, W. & Matter, A. Ann. N. Y. Acad. Sci. 359, 9-23 (1981).
`17. Medawar, P. B. & Hunt, R. Immunology 42, 349-353 (1981).
`18. Medawar, P. B., Hum. R. & Merlin, 1. Proc. R. Soc. Lond. B206, 265-280 (1979).
`19. Malkovsky, M, er al. J. Irnmun. 130, 785-790 (1983).
`20. Loveland, B. E., Hogarth, P. M., Ceredig, Rh. & McKenzie, I.F.C. J. exp. Med. 153,
`1044-1057 (1981).
`21. Loveland, B. E. & McKenzie, I. F. C. Transplantation 33, 217-221 (1982).
`22. Moon, R. C., Grubbs, C. J. & Sporn, M. B. Cancer Res. 36. 2626-2630 (1976).
`23. Malkovsky, M., Asherson, C. L., Stockinger, B. & Watkins, M. C. Nature 300, 652-655
`(1982).
`24. Hughes, W. L. 81' al. Fedn Prac. 23, 640-648 (1964).
`25. Julius, M. 1-1., Simpson, E. & Herzenberg, L. A. Eur. J. Immun. 3, 645-649 (1973).
`26. Mage, M. G., MCI-lugh, L. L. & Rothstein, T. L. J. Immun. Math. 15, 47-56 (1977).
`27. Mags, M. 21 al. Eur. J. Immun. 11, 228-235 (1981).
`28. Zembala, M. A., Asherson, G. L., James, B. M. B.. Stein, V. E. & Watkins. M. C. J.
`Imn-um. 129, 1823-1829 (1982).
`29. Gorini, G., Medgyesi, G. A. 8: Doria, G. J. Imrnun. 103, 1132-1142 (1969).
`30. Abehsira, 0., Edwards, A. & Simpson, E. Eur. J. Immun. 11, 275-281 (1981).
`31. Simon, M. M. er al. Eur. J. Immun. 11, 246-250 (1981).
`
`Transier of a cloned immunoglobulin
`light-chain gene to
`mutant hyhridorna cells
`restores specific antibody production
`
`Atsuo Ochi, Robert G. llawley,
`Marc E. Shulman* & Nohumichi Hozumi
`
`Ontario Cancer Institute and Department of Medical Biophysics,
`University of Toronto, 500 Sherboume Street, Toronto,
`Canada M4X 1K9
`* Rheumatic Disease Unit, Wellesley Hospital, and
`Department of Medical Biophysics, University of Toronto,
`Toronto, Canada M4Y 113
`
`The expression of immunoglobulin (lg) genes is regulated at
`several
`levels. For example, although at-chain production
`requires a DNA rearrangement that juxtaposes variable and
`joining segments‘, this rearrangement is not suficient for K-
`chain gene expression; that is, some cell types do not permit
`immunoglobulin production“. The mechanisms responsible
`for the regulation of the expression.of rearranged immuno-
`globulin genes are poorly understood. The technique of modify-
`ing cloned genes in vitro and transferring the modified genes
`to cells in culture provides a tool for identifying the structural
`features required for gene expression. To analyse immuno-
`globulin genes in this manner, however, it is iirst necessary to
`use, as recipients, cells that normally permit immunoglobulin
`production. We report here that a cloned ac-chain gene is
`expressed in immunoglobulin-producing hybridoma cells. Fur-
`thermore, the product oi the transferred K-chain gene is capable
`of restoring specific antibody production to the transformed
`cells.
`
`The hybridoma Sp603 produces IgM(r<) specific for the hap-
`ten 2,4,6-trinitrophenyl (TNP)5. The rearranged gene encoding
`the TNP—specific K chain (K-nvp) has been cloned . As recipient
`cells, we used the mutant cell line igk-14 which was derived
`from Sp603 and does not produce the Km chain. As shown
`in Fig. 3, the Km gene is apparently deleted from the igk-14
`cell line. Because the igk—14 cells still produce the TNP—specific
`p. heavy chain, it would be expected that the expression of the
`Km; gene in these cells would restore the production of TNP-
`specific IgM. To select for cells that have taken up the K1-Np
`gene, the cloned K-mp gene, designated TK1, was inserted into
`the plasmid pSV2-neo, which contains a bacterial phos-
`photransferase gene (neo) and confers resistance to the amino-
`glycoside antibiotic G418 (ref. 7). In the present study, we have
`used two recombinant plasmids: in the plasmid pT-TK1, TK1
`was inserted so that the direction of transcription would be in
`the same direction as transcription initiated from the SV40
`early promoter;
`in pR-TKI,
`the orientation of the gene is
`reversed (Fig. 1).
`To transfer the DNA, bacteria harbouring the pT—T;<1 and
`pR—T:<1 plasmids were converted to protoplasts and fused with
`igk-14, after the method of Schafiner“. G418-resistant transfor-
`mants of igk—14 were then selected as described in the legend
`to Table 1. The frequency of G418-resistant cells ranged from
`5 X 107" to 10'5 per input igk-14 cell, and was comparable for
`the PT-TK1, pR-TK1 and pSV2—neo plasmids. The resistant
`cells were then tested for the ability to make TNP—specific
`plaques. By this criterion about 10% of the G418-resistant
`transformarrts from PT-TK1 and about 30% of the transfor-
`mants from pR-TK1 made TNP—specific IgM. By contrast, of
`30 G418-resistant transformants from the pSV2-neo vector
`alone, none made TNP—specific plaques.
`_
`Representative transformants were selected, cloned by limit-
`ing dilution and studied further. The production of the K-rNP
`chain has been assayed by TNP—specific haemagglutination and
`
`0028-0836/83/120340-0350‘ 00
`
`Genzyme Ex. 1021, pg 598
`
`© 1983 Macmillan Journals Lid
`
`Genzyme Ex. 1021, pg 598
`
`

`
`' NATURE VOL. 302 24 MARCH 1983
`
`————-— i"(')'|\:,'.‘;'IUR”‘E
`
`
`
`DER 322 ori
`
`5V4o°"
`
`Fig. 1 Structure of T.-<1 transducing plasmids. The TKJ fragment
`(9.6 kb)5 was inserted into the BamHI site of pSV2-neo (donated
`by P. Berg)7 and transfected into Escherichia coli cells (C600) to
`obtain the two types of recombinant, pT-TK1 (TK1 inserted in
`tandem with the SV40 early promoter) and pR-Tk 1 (T7c1 orienta-
`tion reversed with respect to the SV40 early promoter). The
`directions of transcription of the K'rNp gene and SV4O early region
`are indicated by arrows.
`
`'
`
`‘ plaque formation (Table 1). Synthesis of the Km; chain has
`also been measured by SDS-polyacrylamide gel electrophoresis
`: (PAGE) (Fig. 2). The recipient cells igk-14 still produce the K
`, chain from the myeloma X63-Ag8 used to generate the parental
`_, Sp603 hybridoma, and this myeloma K chain migrates more
`slowly than the Kmp protein. Low level production of the Km,
`chain by R11L3 can be detected both as low titre haemagg1uti-
`nation and as a weak band on SDS-PAGE. In general, the
`intensities of the bands corresponding to the KTN}: chain are
`roughly proportional to the TNP-specific haemagglutination
`titres.
`To analyse the Kmp genes in the transformed cell lines,
`transformant DNA was digested with the restriction endonu-
`‘_ clease BamHI, fractionated by agarose gel electrophoresis and
`transferred to nitrocellulose. The blot was then probed with a
`cDNA clone of the K constant-region gene segment (Fig. 3).
`Previous work has shown that this probe detects three K-chain
`A genes in DNA from the Sp603 hybridoma—the bands at 5.9
`and 5.4 kilobases (kb) correspond to K-chain genes donated by
`the myeloma parent; the band at 9.6 kb represents the K-mp
`gene“, and this band is not observed in the case of igk-14. For
`» all the G418—resistant transformants tested, including the T1L2
`cells which do not make TNP-specific IgM, a band at 9.6 kb
`was observed with this probe. Results from DNA blot analysis
`of high molecular weight transformant DNA before and after
`digestion with the restriction endonuclease EcoRI
`(which
`cleaves the recombinant plasmids once) suggest that the trans-
`ferred sequences are integrated into cellular DNA as tandem
`oligomers (data not shown). These results are consistent with
`those obtained by other investigators using the pSV2 transfer
`vectors7'9"°.
`We can estimate the copy number of the K-nqp gene in the
`transformants by comparing the intensity of the band corres-
`ponding to the Km; gene in DNA from the transform-ants with
`the intensity of the band corresponding to the Kfivp gene in the
`DNA of Sp603 which apparently contains one copy of the Km;
`gene per cells. By this criterion, the transformants T3L2 and
`R31L4 have multiple copies. of the Km,» gene per cell, while
`A T1L2 and R11L3 contain about 1 copy per cell. It is interesting
`that the transformant R31L4 makes more K;-Np chain than does
`T3L2, although T3L2 has more copies of the Kn.-P gene. Fur-
`thermore, R31L4 makes about 10-fold less K-mp chain per gene
`copy than does the wild-type hybridoma, although it should be
`pointed out that we do not know if all copies of the Kmp gene
`in R31L4 function equally efficiently. This variability in gene
`
`.
`
`
`
`Identification of romp-chain production in hybridoma cell
`Fig. 2
`lines and pT-TK1 and pR-TK1 transformants. Lane a, igk-14;
`lane b, T1L2; lane c, T3L2; lane :1’, R11L3; lane e, R31L4; lane
`f, Sp603. Secreted immunoglobulin was radiolabelled by incubat-
`ing cells for 18h in leucine-free Dulbecco’s modified Eagle’s
`medium containing “C-leucine (5 u.Ciml_l) and dialysed fetal
`calf serum (5%). Immunoglobulin was reduced and culture super-
`natants analysed by SDS-PAGE as described previouslys.
`
`Table 1 Secretion of TNP-specific lgM by G418-resistant ,
`transformants
`
`Vector
`pT-TK1
`
`pR-TK1
`
`Cell lines
`
`Sp603
`igk-14
`Transformants
`T1I.2
`T3L2
`T4L1
`T12e
`Tl7l.1_
`T19L1
`'I‘21L2
`RZL6
`R9L3
`R10L18
`R1 113
`R20L1
`R22L1
`R31L4
`
`Haemagglutination
`titre
`
`TNP plaque
`formation
`
`1 / 1,280
`< 1 /2
`
`<1/2
`1/160
`< 1/2
`<1 /2
`1/20
`<1 /2
`<1 /2
`1/1,280
`<1 /2
`<1 /2
`1/20
`< 1/2
`1 / 640
`1/320
`
`+
`-
`
`—
`+
`—
`—
`—
`—
`—
`+
`-
`—
`-
`—
`+
`+
`
`The igk-14 cells were fused with bacterial protoplasts containing
`either the pT-TK1 or pR-TK1 plasmids. The methods for increasing
`the plasmid copy -number and making protoplasts have been described
`elsewhere”. About 101° protoplasts were collected by centrifugation.
`107 igk-14 cells, grown as described previouslys, were washed’ and
`resuspended in Gibco H21 medium, and centrifuged onto the protoplast
`pellet. The protoplasts and igk-14 cells were then fused with polyethyl-
`ene glycol 1000 (PEG), as described by Taniguchi and Miller for the
`production of T-cell hybridomas”. Briefly, after centrifugation, the
`cell-protoplast pellet was gently resuspended in 2 ml of H21 medium
`containing 40% PEG and 10% dimethyl sulphoxide. After 15 s, the
`mixture was added to an equal volume of H21 medium containing 50%
`PEG and mixing was continued for a further 15 s. The cells were then
`diluted to 50 ml with H21 medium containing 20% fetal calf serum,
`washed once in the same medium and plated in 24-well culture dishes
`at a cell density of 105 cells per well. After 24 h, the fused cells were
`selected in H21 medium containing 1n1gml'1 of 6418 (a gift of
`Schering Corporation). The transformants resistant
`to C-418 were
`screened for the production of TNP-specific lgM by testing for TN?-
`specific plaque formation. Representative transformants were then
`cloned by limiting dilution. Culture supernatants were tested for
`haemagglutination of TNP-coupled sheep red cells (TNP-SRC) as
`described elsewhere5. The sensitivity of the assay was enhanced by
`including monoclonalrat anti-p. antibody C2-23, as described else-
`where (M. Potash 8.’ al.,
`in preparation). Plaquing was done on
`~10“ cells, also as described previously’.
`
`
`
`Genzyme Ex. 1021, pg 599
`
`Genzyme Ex. 1021, pg 599
`
`

`
`342
`
`NATURE VOL. 302 24 MARCH 1983
`
`LETTERS TO NATURE
`11. Kelley. D. B., Coleclough, C. & Perry, R. 1’. Cell 29, 681-689 (1982).
`12. I-Iamlyn, P. H., Brownlee, G. G., Chang, C. C., Gait. M. J. & Milstein.-C. Cell 15.
`1067-1075 (1978).
`13. Falkner. F. G. & Zachau, H. G. Nature 298, 286-288 (1982).
`14. Sandri-Goldin, R. M., Goldin, A. I... Levine, M. & Glorioso. J. C. Molec. cell. Biol. 1,
`743-752 (1981).
`15. Taniguchi. M. & Miller. J. F. A. P. J. exp. Med. 148, 373-382 (1978).
`16. Southern. E. M. J. malec. Biol. 97, 503-517 (1975).
`17. Rice, D. & Baltimore. D. Prac. nam. Acad. Sci. U.$.A. 79, 7862-7865 (1982).
`18. Oi. V. T., Morrison, S. L.. Herzenberg, L. A. & Berg, P. Prac. narn. Acad. Sci. U.S.A.
`80, 825-829 (1983).
`
`
`Deduced amino acid sequence
`irons the bovine
`oxytocin-ueurophysin E
`precursor cDNA.
`
`H. Land*:i, M. Grez*:l:, S. Rupperf“, H. Schrnalei,
`M. Rehbeini‘, D. Richter‘? & G. Schiitz*
`* Institute of Cell and Tumor Biology, German Cancer Research
`Center, Im Neuenheimer Feld 280, D-6900 Heidelberg, FRG
`‘r Institut fiir Physiologische Chemie, Abteilung Zellbiochemie,
`Universitiit Hamburg, UKE, 2000 Hamburg 20, FRG
`
`The nonapeptide hormone oxytocin-like arginine-vasopressin
`(AVP)“‘ is synthesized as part of a larger precursor polypep-
`tide. The precursor also includes the neurophysin molecule with
`which the hormone is associated in the nenrosecretory granules
`of the hypothalamo-pituitary tract. A protein of molecular
`weight (M.) ~ 20,000 has been isolated from supraoptic nuclei
`of rat hypothalami which, after tryptic cleavage, released a
`neurophysin-like molecule of M,~ 10,000 and an oligopeptide
`related to oxytocins. This result was complemented by in uitro
`translation of bovine hypothalamic mRNA”. Among the
`primary
`translation
`products
`a
`single
`polypeptide
`of
`M,~16,500 was shown to contain antigenic determinants rec-
`ognized by specific antisera against bovine neurophysin I and
`oxytocin. Here we report the amino acid sequence of the bovine
`oxytocin—neurophysin I (OT-Npl) precursor which was derived
`from sequence analysis of the cloned cDNA. As is the case for
`the bovine arginine-vasopressin-neurophyin II (AVP-Npll)
`precursor‘, the signal sequence of the OT-Nplprecursor is
`immediately followed by the nonapeptide hormone which is
`connected to neurophysin l by a Gly-=Lys-Arg sequence. A
`striking feature of the nucleic acid sequence is the 197-nnclem
`tide long perfect homology with the AVP-Npfl precursor
`mRNA sequence encoding the conserved middle part of
`neurophysins I and ll.
`A cDNA library of bovine hypothalamic mRNA‘ was
`screened for plasmids containing the mRNA sequence for the
`OT-Npl precursor. Bovine neurophysins I and II show nearly
`80% homology in their amino acid sequences,
`including a
`complete homology between amino acids 10 and 74, so con-
`siderable cross-hybridization was expected between the mRNA
`sequences for the AVP-NpII precursor and the OT-Npl pre-
`cursor.
`
`The cloned cDNA encoding the AVP—NpII precursor‘ was
`therefore chosen as a hybridization probe for in situ colony
`screening9. Out of 5,000 recombinants, 63 clones gave a positive
`hybridization signal. Restriction analysis of
`the plasmids
`revealed two groups of 47 and 16 members containing different
`types of CDNA inserts (see Fig. 1 for examples). The first group
`represented cDNA sequences specific for the AVP-NpII pre-
`cursor‘. Sequence analysis of members of the second group
`(Fig. 1) showed that these contained OT—NpI precursor-specific
`sequences.
`Figure 2 shows the nucleotide sequences of the cloned OT-
`Npl precursor CDNA and of the previously described AVP—
`NpII precursor CDNA‘ plus the predicted amino acid sequences.
`
`1 Present addresses: MIT Center for Cancer Research, 77 Massachusetts Avenue,
`Cambridge, Massachusetts 02138. USA (H.L.); University of Southern California, School of
`Medicine, Department of Microbiology. 2025 Zonal Avenue, Los Angeles, California
`90033. USA (M.G.).
`
`
`
`.1’_._..-4;-._.
`
`
`
`Fig. 3 Blot hybridization of DNAs from hybridoma cell lines
`and p'l'—TK1 and pR-TK1 transformants. Lane a,.igk-14; lane b,
`T1L2; lane c, T3L2; lane d, R11L3; lane e, R31L/l; lane f, Sp603.
`BamHI-digested DNA samples (20 ug) were electrophoresed
`through a 1% agarose gel at 2 V cm" for 40 h. After transfer to
`nitrocellulose”, the blot was hybridized with a 321’-labelled cDNA
`clone of the K constant-region gene segment (pL21-5 provided
`by R. Wall) by a method described elsewhere‘.
`
`'
`
`expression raises the question of whether all the regulatory
`elements of the normal K-1-Np gene are present or functioning
`on the cloned fragment. The messenger RNA cap sites have
`been identified for several immunoglobulin K-chain genes“. In
`all cases, the cap site seems to be within 30 base pairs (bp) of
`the initiation codon. As the TK1 fragment has 5 kb of DNA
`upstream of the initiation codon,
`it is likely that the DNA
`fragment carries the Kjwp gene promoter. Similarly, the poly(A)
`addition site is estimated to lie 211 bp downstream of the
`constant-region gene segment”, which is well within the 1.2 kb
`of downstream flanking DNA. Experiments are in progress to
`determine the molecular basis for the differences in the level
`of expression of the Km; gene in the various transformants.
`Falkner and Zachau have studied the transient expression of
`mouse immunobulin K-chain genes in African green monkey
`cells (CV1), HeLa cells and mouse L cells”. In the case of the
`monkey CV1 cells and the HeLa cells, the K-chain gene was
`expressed only when transcription of the gene was placed under
`the’ direct control of an SV40 promoter after removal of the
`putative K -chain gene promoter region. In the case of the mouse
`L cells, the K-chain gene was not expressed. There are many
`structural differences between the vectors used by Falkner and
`Zachau and those used here. On the other hand, differences in
`the cellular environments might underlie the different require-
`ments for K-(chain gene expression. It should be possible to
`resolve these differences by using the gene transfer .system
`described here on cells of different types.
`'
`This work was supported by grants from the MRC of Canada,
`the National Cancer Institute of Canada, the Arthritis Society
`of Canada and the Allstate Foundation. A.O. was supported
`by a research fellowship of the National Cancer Institute of
`Canada. R.G.H. was supported by a studentship of the MRC
`of Canada.
`Note added in proof: Rice and Baltimore” and Oi er al.” have
`recently reported the expression of cloned K light chain genes
`in transformed lymphoid cells.
`Received 17 November 1982; accepted 19 January 1983.
`Seidman, J. (3.. Max, E. E. & Leder, P. Nature 280. 370-375 (1979).
`. Parslow. T. G. & Granner, D. K. Nature 299, 449-451 (1982).
`Cofiino, P., Knowles. B., Natl-ienson, S. G. & Scharfi, M. D. Nature new Biol. 231, 87-90
`(1971).
`Ar—Rushdi. A.. Tan. K. B. & Croce. C. M. Somatic Cell Genet. 8, 151-161 (1982).
`Kfihler, G. & Shulman, M. J. Eur. J. Immun. 10, 467-476 (1980).
`. I-Iawley, R. G., Shulman, M. 1., Murialdo, I-I.. Gibson, D. M. & Hozumi. N. Prac. nam.
`Acmi. Sci. U.S.A. 79, 7425-7429 (1982).
`Southern. P. J. & Berg, 1’. J. malec. appl. Genet. 1, 327-341 (1982).
`Schaffner, W. Prac. nam. Acad. Sci. U.S.A. 77, 2163-2167 (1980).
`Mulligan, R. C. & Berg. P. Proc. nam. Acad. Sci. U.S.A. 78. 2072-2076 (1981).
`. Canaani. D. & Berg. P. Prac. nam. Acad. Sci. U.S.A. 79, 5166-5170 (1982).
`
`
`
`
`
`C)09“."¢".V'.“5‘""?"
`
`0028.-0836/83/120342—03$01.00
`
`Genzyme Ex. 1021, pg 600
`
`‘
`
`'
`
`' © 19s3'Macmiuan Journals Ltd
`
`Genzyme Ex. 1021, pg 600

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket